Overview of Dr. Pike
Dr. Luke Pike is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Boston Children's Hospital. He received his medical degree from Yale School of Medicine and has been in practice 1 year. He is one of 8 doctors at Boston Children's Hospital and one of 106 doctors at Memorial Sloan Kettering Cancer Center who specialize in Radiation Oncology. He has more than 40 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
- Massachusetts General HospitalInternship, Preliminary Year, 2015 - 2016
- Yale School of MedicineClass of 2015
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology
Certifications & Licensure
- FL State Medical License 2023 - Present
- NY State Medical License 2020 - 2026
- NJ State Medical License 2020 - 2025
- MA State Medical License 2015 - 2022
- American Board of Radiology Radiation Oncology
Clinical Trials
- A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain Start of enrollment: 2022 Jun 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 10 citationsGenomic analysis and clinical correlations of non-small cell lung cancer brain metastasis.Anna Skakodub, Henry Walch, Kathryn R Tringale, Jordan Eichholz, Brandon S Imber
Nature Communications. 2023-08-17 - 110 citationsThe Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R.G. Pike, Andrew Bang, Brandon A. Mahal, Allison Taylor, Monica Krishnan
International Journal of Radiation Oncology, Biology, Physics. 2019-01-01 - 140 citationsThe histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia and is a key mediator of estrogen induced growthJun Yang, Adrian M. Jubb, Luke R.G. Pike, Francesca M. Buffa, Helen Turley
Cancer Research. 2010-08-15
Press Mentions
- Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part II)September 18th, 2024
- Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part I)September 5th, 2024
- MSK Research Highlights, August 13, 2024August 13th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: